Opioid Use Disorder
📧 Sign up to get email alerts when something new happens for Opioid Use Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2018-02-01FDA Approved: BUPRENORPHINE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for buprenorphine submitted by Hikma Pharmaceuticals USA Inc. (ANDA).
-
FDA approval · 2018-02-01FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Lannett Company, Inc.)
The FDA approved a supplemental application for a generic buprenorphine and naloxone product manufactured by Lannett Company, expanding acce…
-
FDA approval · 2018-02-01FDA Approved: BUPRENORPHINE HYDROCHLORIDE — Supplemental Application (Advagen Pharma Ltd)
FDA approved a supplemental application for buprenorphine hydrochloride by Advagen Pharma Ltd, granting approval for a generic product.
-
FDA approval · 2018-01-31FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Methadone Hydrochloride from Hikma Pharmaceuticals USA Inc. under ANDA 087997.
-
FDA approval · 2018-01-31FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approves a supplemental application for Methadone Hydrochloride (generic) from Hikma Pharmaceuticals USA Inc., supporting continued appr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2018-01-31FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (VistaPharm, LLC)
FDA approved a supplemental application for methadone hydrochloride by VistaPharm, LLC under ANDA090707, authorizing a revised/expanded labe…
-
FDA approval · 2018-01-31FDA Approved: BUPRENORPHINE HCL AND NALOXONE HCL — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved Amneal Pharmaceuticals' supplemental application for buprenorphine HCl and naloxone HCl (buprenorphine and naloxone), under…
-
FDA approval · 2018-01-31FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental ANDA for BUPRENORPHINE AND NALOXONE from Actavis Pharma, Inc., approving its generic product for the treatment o…
-
FDA approval · 2018-01-31FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma)
FDA approved a supplemental application for a buprenorphine and naloxone product supplied by PAI Holdings/PAI Pharma, marking a supplemental…
-
FDA approval · 2018-01-31FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' supplemental application for buprenorphine and naloxone. This action updates the product's label…
-
FDA approval · 2018-01-31FDA Approved: BUPRENORPHINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' supplemental application for buprenorphine (generic). The buprenorphine product is used to treat…
-
CLINICAL_TRIALS trial_result · 2018-01-19Clinical Trial Update: Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment [Phase 4]
Phase 4 trial comparing extended-release naltrexone to buprenorphine for opioid use disorder has completed with results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2017-12-26Clinical Trial Update: Employment-Based Depot Naltrexone Clinical Trial II [Phase 2]
Phase 2 clinical trial update for employment-based depot naltrexone in opiate dependence; study completed with results posted in 2017.
-
FDA approval · 2017-12-13FDA Approved: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE — Original Application (SpecGx LLC)
FDA approved a generic buprenorphine hydrochloride and naloxone hydrochloride dihydrate product for opioid dependence. This is the Original …
-
CLINICAL_TRIALS trial_result · 2017-12-07Clinical Trial Update: Cognitive Function and Addiction Under Opioid Tapering [Phase 3]
Phase 3 clinical trial update on cognitive function and addiction during opioid tapering in adults with chronic pain and opioid use disorder…
-
CLINICAL_TRIALS trial_result · 2017-12-05Clinical Trial Update: Efficacy of Acupuncture as an Adjunct to Methadone Treatment Services for Heroin Addicts [NA]
This clinical trial evaluates acupuncture as an adjunct to methadone treatment for heroin addiction, focusing on opioid withdrawal symptoms …
-
FDA approval · 2017-11-30FDA Approved: SUBLOCADE — Original Application (Indivior Inc.)
FDA approved SUBLOCADE, a long-acting injectable buprenorphine, under the original application for the treatment of opioid use disorder.
-
CLINICAL_TRIALS trial_result · 2017-11-29Clinical Trial Update: Pilot Study of Contingency Management for Smoking Cessation [NA]
A pilot clinical trial evaluating contingency management for smoking cessation has completed.
-
CLINICAL_TRIALS trial_result · 2017-11-21Clinical Trial Update: Neonatal and Maternal Effects of Buprenorphine and Methadone
This trial evaluated neonatal and maternal outcomes of buprenorphine versus methadone treatment in opioid-maintained pregnant women. The stu…
-
CLINICAL_TRIALS trial_result · 2017-11-17Clinical Trial Update: Functional Magnetic Resonance Imaging of Opioid Withdrawal in Healthy Human Volunteers [NA]
A Stanford functional MRI study investigated brain activity during opioid withdrawal in healthy volunteers; the trial is completed and resul…
-
CLINICAL_TRIALS trial_result · 2017-11-01Clinical Trial Update: Feasibility Study of Take-Home LAAM Medication - 3 [Phase 4]
A Phase 4 feasibility trial testing take-home LAAM for opioid-related disorders has completed.
-
FDA approval · 2017-10-27FDA Approved: METHADONE HYDROCHLORIDE — Original Application (Long Grove Pharmaceuticals, LLC)
FDA approves Long Grove Pharmaceuticals' methadone hydrochloride under an original application (ANDA 208306), establishing its generic produ…
-
CLINICAL_TRIALS trial_result · 2017-10-26Clinical Trial Update: Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction [Phase 1]
A Phase 1 clinical trial update evaluating the exposures of lofexidine and its major metabolites in subjects seeking buprenorphine dose redu…
-
CLINICAL_TRIALS trial_result · 2017-10-23Clinical Trial Update: Treatment Study Using Depot Naltrexone (1/6) Philadelphia Coord/Data Mgmt Site [Phase 2, Phase 3]
Completed Phase 2/3 trial evaluating depot naltrexone for opioid addiction; results were posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-10-17Clinical Trial Update: The Discriminative Effects of Tramadol in Humans [Phase 1, Phase 2]
Phase 1 and Phase 2 studies explored the discriminative effects of tramadol in humans for opioid use disorder and stimulant use disorder; re…